Deciphera Pharmaceuticals, Inc. ( DCPH Quick Quote DCPH - Free Report) reported a loss of $1.06 per share for first-quarter 2021, narrower than the Zacks Consensus Estimate of a loss of $1.08 and the year-ago quarter’s loss of $1.36.
Total net revenues were $25.1 million for the quarter, which beat the Zacks Consensus Estimate of $23 million. Total revenues included $20 million of revenues from Qinlock and $5.2 million of collaboration revenues. Sales of Qinlock in the United States were $19.3 million and ex-U.S. sales of Qinlock were $0.7 million.
Shares of the company have lost 29.3% in the year so far compared with the
industry’s decline of 5.9%. Quarter in Details
In May 2020, Qinlock was approved by the FDA for the treatment of adult patients with advanced gastrointestinal stromal tumors (GIST) who have received prior treatment with three or more kinase inhibitors, including imatinib.
Research and development expenses were $55.7 million, up from $51.4 million primarily due to personnel and preclinical costs in the year-ago quarter.
Selling, general and administrative expenses were $30.7 million, up from $23.9 million in the year-ago quarter due to personnel costs as well as external spend related to professional fees, including those associated with establishing a targeted commercial infrastructure in key European markets to support a potential launch of Qinlock in Europe, if approved.
Deciphera plans to initiate a phase I/IIb study of QINLOCK in combination with Mektovi (binimetinib), an approved MEK inhibitor, to address one of the potential mechanisms of resistance to kinase inhibition, reactivation of the MAPK pathway, in post-imatinib GIST patients.
The company completed enrollment in the INTRIGUE phase III study evaluating the efficacy and safety of Qinlock compared to
Pfizer’s ( PFE Quick Quote PFE - Free Report) Sutent (sunitinib) in patients with second-line GIST. Top-line results for this study are expected in the fourth quarter of 2021. Our Take
The initial uptake of Qinlock has been encouraging and the company is working to expand access to this medicine globally. The successful results of the INTRIGUE study (expected later in the year) will broaden the targeted market further (larger, second-line patient population).
Zacks Rank & Stocks to Consider
Deciphera currently has a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the healthcare space are
Ironwood Pharmaceuticals, Inc. ( IRWD Quick Quote IRWD - Free Report) and Pacira BioSciences ( PCRX Quick Quote PCRX - Free Report) , which currently carry a Zacks Rank #2 (Buy). You can see . the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here
Earnings estimates for Ironwood Pharmaceuticals moved up 2 cents for 2021 in the past 30 days.
Earnings estimates for Pacira rose 6 cents for 2021 in the past 30 days.
Infrastructure Stock Boom to Sweep America
A massive push to rebuild the crumbling U.S. infrastructure will soon be underway. It’s bipartisan, urgent, and inevitable. Trillions will be spent. Fortunes will be made.
The only question is “Will you get into the right stocks early when their growth potential is greatest?”
Zacks has released a Special Report to help you do just that, and today it’s free. Discover 7 special companies that look to gain the most from construction and repair to roads, bridges, and buildings, plus cargo hauling and energy transformation on an almost unimaginable scale.
Download FREE: How to Profit from Trillions on Spending for Infrastructure >>